Clinical-immunological Features of Anti-NMDAR Encephalitis
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Anti NMDA Receptor Encephalitis
- Sponsor
- Hospices Civils de Lyon
- Enrollment
- 400
- Locations
- 1
- Primary Endpoint
- Modified Rankin scale (mRS)
- Status
- Active, not recruiting
- Last Updated
- 3 years ago
Overview
Brief Summary
Using a retrospective cohort of 501 patients with anti-NMDAR encephalitis to assess clinical and immunological prognostic biomarkers
Investigators
Eligibility Criteria
Inclusion Criteria
- •Patient with neurological disorder
- •Patient with NMDAR antibodies in sera or CSF
Exclusion Criteria
- •- No available clinical data
- •Patient without NMDAR antibodies or neurological disorder
Outcomes
Primary Outcomes
Modified Rankin scale (mRS)
Time Frame: Baseline
Scale for measuring the degree of dependence in the daily activities of people who have suffered of neurological disability. 0 - No symptoms. 1. - No significant disability. Able to carry out all usual activities, despite some symptoms. 2. - Slight disability. Able to look after own affairs without assistance, but unable to carry out all previous activities. 3. - Moderate disability. Requires some help, but able to walk unassisted. 4. - Moderately severe disability. Unable to attend to own bodily needs without assistance, and unable to walk unassisted. 5. - Severe disability. Requires constant nursing care and attention, bedridden, incontinent. 6. - Dead.